Quimpharma has completed the divestiture of a product portfolio to Megalabs
April 2026 — Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Quimpharma is a Mexican pharmaceutical company focused on the development, manufacture and distribution of prescription, over-the-counter (OTC), food supplement and dermocosmetic products. With over 22 years of history, the company has established a strong position in the Mexican market, supported by a robust R&D division and a portfolio of more than 40 products across key therapeutic categories. The company operates a manufacturing facility with liquid and solid production lines, a distribution center and corporate offices in Mexico City, enabling nationwide reach and consistent product availability.
Megalabs México, through Italmex, is part of Megalabs, a Uruguay-based pharmaceutical group with a strong presence across Latin America. The company develops and commercializes innovative, high-quality pharmaceutical products, dermocosmetics and nutritional supplements across multiple therapeutic areas, working closely with healthcare professionals to support patients’ health and wellbeing throughout Mexico and the region.
Our role in the transaction
Oaklins’ team in Mexico acted as the exclusive sell-side advisor to Quimpharma in the divestiture of a product portfolio to Megalabs. This transaction highlights Oaklins’ expertise in the healthcare sector and reinforces its strong track record advising mid-market companies through complex, cross-border processes.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more